Click Here to
News, Updates,
& More
Stay Up
to Date

Lynch Syndrome

The novel drug sacituzumab govitecan is showing significant promise in HER2-negative breast cancers. “The benefit was durable, with an estimated medical duration of response of 7.4 months,” reported Aditya Bardia, MD, MPH.

Results 1 - 1 of 1